Why Traditional HCP Engagement Models Are No Longer Fit for Purpose

Connect

Scientific innovation has accelerated. But the commercial models used to engage HCPs have not kept pace.


At Fierce Pharma Week 2026, we challenged traditional targeting models and explored how diagnostic intelligence can bring greater clinical context and precision to the moments when treatment decisions are taking shape.

Speaker: Jordan Clark, Chief Customer Officer, Diaceutics

 

“Claims data can be 15 to 90 days old. Diagnostic intelligence can reveal clinically relevant change within 24 hours”.
– Jordan Clark, Chief Customer Officer, Diaceutics


Key highlights


Claims data may be 15 to 90 days old
Historical claims data can show what happened. But it may not reveal who has responsibility for a patient now, or when the next treatment decision is taking shape.

Campaign timing is not decision timing
The session challenges commercial teams to move beyond target lists and campaign sequences built on retrospective activity, and focus instead on the window in which relevant information can still support a treatment decision.

Diagnostic intelligence can make 24 hours matter
Clinically rich diagnostic signals can help identify the relevant HCP while a decision is still forming, making engagement more timely, relevant and connected to the patient journey. 

Want to engage the right HCP while treatment decisions are still forming?

Diaceutics Signal gives commercial teams visibility of therapy-relevant diagnostic activity while there is still time to act.
By identifying therapy-relevant diagnostic events in as little as 24 hours and linking them to the treating HCP, Signal helps teams focus engagement where it matters most.

<strong>CONTACT US</strong>

Continue the conversation


For a closer look at what happens once a meaningful signal is identified, watch our panel discussion at Fierce Pharma Week, “Drive Omnichannel Decisions With Real-World Diagnostic Data and Intelligence”. The panel explores how diagnostic and real-world signals can help commercial teams prioritise who to engage, when engagement is most relevant and where to focus limited attention and investment. 

closing-the-gap

Better testing alone does not ensure that every eligible patient reaches treatment. The Close the Gap report reveals where patients are still being lost between diagnosis, treatment decisions and therapy adoption, and what needs to change to close the gap between scientific innovation and patient impact.

This is the vision behind Precision for All: making precision the standard for every eligible patient, not the privilege of the few.

Unlock the full potential of your diagnostic-driven therapy and book a meeting with our team today

We’ve been with pharma and biotech companies for over 20 years, helping them to make more informed diagnostic and therapeutic decisions based on real-world data. Our platforms and tools provide global insight from a network of laboratories across 50+ countries.

This unparalleled visibility into real-world testing helps support therapy programs across oncology, cardiology, neurology, autoimmune, rare diseases, and many more.

<strong>CONTACT US</strong>
Share:

Newsletter sign up

Sign up to our bi-weekly newsletter covering the latest insights to optimize commercialization of diagnostic driven therapies to help empower your decisions.

READY TO DO COMMERCIALIZATION DIFFERENTLY?

Every patient journey contains opportunities to improve testing, engagement, and adoption. We can help you find them so more people get the right therapy sooner.

You might also be interested in?